884652-29-3

Upstream product

• 5451-40-1 2,6-dichloro-7H-purine 
• 60410-16-4 (1R,4S)-4-hydroxy-2-cyclopentene-1-yl acetate 
• 884654-01-7 (1S,2R,3S,5R)-3-(bis-(tert-butyloxycarbonyl))-amino-5-[2-chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-cyclopentane-1,2-diol 
• 955114-75-7 (1 S,2R,3S,5R)-3-Amino-5-(2,6-dichloro-purin-9-yl)-cyclopentane-1,2-diol trifluoroacetate 
• 884654-00-6 {2-chloro-9-[(1R,4S)-4-(di-boc-amino)-cyclopent-2-enyl]-9H-purin-6-yl}-(2,2-diphenyl-ethyl)-amine 
• 884653-97-8 (1S,2R,3S,5R)-(di-tert-butoxycarbonylamino)-5-(2,6-dichloro-purin-9-yl)-cyclopentane-1,2-diol 
• 884653-96-7 di-boc-[(1S,4R)-4-(2,6-dichloro-purin-9-yl)-cyclopent-2-enyl]-amine 
• 884653-95-6 carbonic acid (1S,4R)-4-(2,6-dichloro-purin-9-yl)-cyclopent-2-enyl ester ethyl ester 
• 79-03-8 propionyl chloride 
• 884653-99-0 N-[(1S,2R,3S,4R)-4-(2,6-dichloro-purin-9-yl)-2.3-dihydroxy-cyclopentyl]-propionamide 
• 3963-62-0 2,2-Diphenylethylamine 

Downstream Products

• 884653-82-1 {(R)-1-[9-((1R,2S,3R,4S)-2,3-dihydroxy-4-propionylamino-cyclopentyl)-6-(2,2-diphenyl-ethylamino)-9H-purin-2-yl]-pyrrolidin-3-yl}-carbamic acid benzyl ester 
• 955969-56-9 C₃₄H₃₉N₉O₅ 
• 955972-63-1 N-{(1S,2R,3S,4R)-4-[6-(2,2-diphenyl-ethylamino)-2-hydrazino-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide 
• 884652-89-5 N-{(1S,2R,3S,4R)-4-[2-((1S,3R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl}-propionamide 
• 884653-85-4 N-[(3aR,4S,6R,6aS)-6-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-yl]-propionamide 
• 884653-84-3 {(R)-1-[9-((3aS,4R,6S,6aR)-2,2-dimethyl-6-propionylamino-tetrahydro-cyclopental[1,3]dioxol-4-yl)-6-(2,2-diphenyl-ethylamino)-9H-purin-2-yl]-pyrrolidin-3-yl}-carbamic acid benzyl ester 
• 955969-22-9 {(R)-1-[9-((1R,2S,3R,4S)-2,3-dihydroxy-4-propionylamino-cyclopentyl)-6-(2,2-diphenyl-ethylamino)-9H-purin-2-yl]-pyrrolidin-3-yl}-carbamic acid tert-butyl ester trifluoroacetate 
• 955969-21-8 {(R)-1-[9-((1R,2S,3R,4S)-2,3-dihydroxy-4-propionylamino-cyclopentyl)-6-(2,2-diphenyl-ethylamino)-9H-purin-2-yl]-pyrrolidin-3-yl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Organic Compounds

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R1, R2 and R3 are as defined herein.

Synthesis and evaluation of two series of 4′-aza-carbocyclic nucleosides as adenosine A2A receptor agonists

The synthesis of two series of 4′-aza-carbocyclic nucleosides are described in which the 4′-substituent is either a reversed amide, relative to the carboxamide of NECA, or an N-bonded heterocycle. Using established purine substitution patterns, potent and

Adenosine Derivatives as A2A Receptor Agonists

A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U1, U2, R1a, R1b, R2 and R3 have the meanings as indicated in the specification, are useful

ORGANIC COMPOUNDS

A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, wherein, Rla, Rlb, R2a, R2b, U1, U2, X1, X2 and L are as defined herein.

ORGANIC COMPOUNDS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein Rl, R2 and R3 are as defined herein.

ORGANIC COMPOUNDS

A compound of formula (I) and their preparation and use as pharmaceuticals wherein R1, R2 and R3 are as defined herein.

PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor,